11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022

American Diabetes Association Professional … - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

[HTML][HTML] Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

HC Gerstein, N Sattar, J Rosenstock… - New England journal …, 2021 - Mass Medical Soc
Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

Trajectories of kidney function in diabetes: a clinicopathological update

M Oshima, M Shimizu, M Yamanouchi… - Nature Reviews …, 2021 - nature.com
Diabetic nephropathy has been traditionally diagnosed based on persistently high
albuminuria and a subsequent decline in glomerular filtration rate (GFR), which is widely …

KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease

IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

[HTML][HTML] Documento de información y consenso para la detección y manejo de la enfermedad renal crónica

R García-Maset, J Bover, JS de la Morena… - nefrologia, 2022 - Elsevier
La enfermedad renal crónica (ERC) es un importante problema de salud pública a nivel
mundial afectando a más del 10% de la población española. Se asocia a elevada …

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in …

AS Levey, RT Gansevoort, J Coresh, LA Inker… - American journal of …, 2020 - Elsevier
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are
currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a …

Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne's thread

A Duni, V Liakopoulos, S Roumeliotis… - International journal of …, 2019 - mdpi.com
Amplification of oxidative stress is present since the early stages of chronic kidney disease
(CKD), holding a key position in the pathogenesis of renal failure. Induction of renal pro …

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

HJL Heerspink, HH Parving, DL Andress, G Bakris… - The Lancet, 2019 - thelancet.com
Background Short-term treatment for people with type 2 diabetes using a low dose of the
selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing …